H.C. Wainwright raises Glaukos stock price target on strong results
H.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the combination of (1) raised full-year net sales guidance and (2) multiple analyst target increases that can reinforce bullish positioning and reduce near-term downside expectations.
Market read
A fresh analyst target raise tied directly to a guidance increase can move short-term sentiment and expectations for GKOS, especially given the stock’s large 1-year run-up.
What to watch
Gross margin strength and liquidity are highlighted, but the article does not quantify durability of iDose TR and Epioxa adoption or competitive/coverage risks that could affect future guidance accuracy.
Background
The piece centers on an analyst price-target increase for Glaukos following its Q2 2026 results and an upward revision to full-year net sales guidance.
Ticker impact
H.C. Wainwright raised its Glaukos price target to $195 from $168 after Glaukos reported Q2 2026 results and lifted full-year net sales guidance.
Likely supportive for GKOS in the near term, but magnitude depends on whether the market already priced in the Q2 beat and guidance raise.
The article provides specific Q2 revenue and guidance numbers plus the analyst’s updated target, which can drive incremental buying from momentum and model-repricing desks.
Market effects
Positive read-through for glaucoma and corneal health peers if investors extrapolate demand momentum for iDose TR and Epioxa.
Limited, as the catalyst is company-specific analyst action in US-listed biotech/medtech.
Low, no cross-border regulatory or commercial deal details beyond US sales growth.
Counterpoint
Despite the revenue beat, Glaukos still reported a net loss, and InvestingPro suggests shares may be overvalued, which could cap upside on any target-driven rally.
Key entities
- public_companyGlaukos Corporation
Reported Q2 2026 revenue of $185.6M and raised full-year 2026 net sales guidance to $680M-$700M; subject of the analyst target change.
- analyst_firmH.C. Wainwright
Raised its GKOS price target to $195 from $168 and maintained a Buy rating after the company’s results.
